Patients with post-COVID fatigue and neuropsychiatric symptoms of long COVID Vitamin D, 25-hydroxyvitamin D, long COVID, post COVID-19
Conditions
Interventions
60,000 IU oral vitamin D2 once weekly for 8 weeks,a placebo (Starch powder capsule) once weekly for 8 weeks
Experimental Dietary Supplement,Placebo Comparator No treatment
Vitamin D2 (Ergocalciferol capsule),placebo (Starch powder capsule)
Sponsors
Faculty of medicine, Thammasat University
The Research Group in Clinical Epidemiology from Faculty of Medicine, Thammasat University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Participants of both sex aged between 18 and 60 years 2. Participants have been tested positive for COVID-19 from Real-Time Polymerase Chain Reaction (RT-PCR) test or Antigen Test Kit (ATK) followed by an RT-PCR/ATK negative test for COVID within 12 months. 3. Participants have been experiencing clinical fatigue or insomnia or depression or anxiety or cognitive impairment after the onset of COVID-19 and symptoms last for at least 1 month. 4. Patients' information can be searched from the EMR system or data of COVID-19 Infectious Disease Control Group, Thammasat Hospital. 5. Able to take the drug orally, comply with study procedures, and provide written informed consent
Exclusion criteria
Exclusion criteria: 1. Patients taking any type of vitamin D supplement in the preceding one month 2. Patient with known allergy or contraindications to vitamin D administration 3. Pregnant or lactating women 4. Any known cardiovascular, pulmonary, renal, or hepatic disease, hypercalcemia, active malignancy, severe infection, or any conditions that, in the opinion of the investigator, were critical health conditions 5. Patients who have major mood disorder (major depressive disorder and bipolar disorder), schizophrenia, major neurocognitive disorder, and sleep disorder before infected with COVID-19. 6. Inability to follow the procedures of the study, for example, due to language problems, severe mental or cognitive disorders, refuse to take blood collection etc. 7. Pre-treatment serum vitamin D level > 50 ng/mL, pre-treatment serum total Ca2+ level > 10.5 mg/DL
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post-Covid fatigue 8-week after intervention 11-items Chalder fatigue scale (CFQ-11) ,Post-covid anxiety and depression 8-week after intervention The twenty-one-item Depression, Anxiety and Stress Scale (DASS-21) ,Post-Covid sleep problems 8-week after intervention The Pittsburgh Sleep Quality Index (PSQI) ,Post-Covid brain fog 8-week after intervention The Addenbrooke's Cognitive Examination III (ACE-III) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in inflammatory markers 8-week after intervention CRP, IL-6 | — |
Countries
Thailand
Contacts
Public ContactVeevarin Charoenporn
Department of Psychiatry, Thammasat university hospital
Outcome results
None listed